Sarepta Therapeutics (SRPT) wasn’t directly implicated in the biotech sector’s credibility crisis last week, but that didn’t stop the company from running into trouble.

The “erroneous” disclosure last Thursday of a serious side effect affecting a single patient with Duchenne muscular dystrophy enrolled in Sarepta’s gene therapy clinical trial sowed confusion, concern, and anger. The stock price took a hit, recovered, then fell some more. All in, Sarepta shares lost 14%.

Continue to STAT Plus to read the full story…

Source link